Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.
Elevation Oncology, Inc. Frequently Asked Questions
What is the ticker symbol for Elevation Oncology, Inc.? What does ELEV stand for in stocks?
ELEV is the stock ticker symbol of Elevation Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Elevation Oncology, Inc. (ELEV)?
As of Wed Dec 04 2024, market cap of Elevation Oncology, Inc. is 34.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ELEV stock?
You can check ELEV's fair value in chart for subscribers.
Is Elevation Oncology, Inc. a good stock to buy?
The fair value guage provides a quick view whether ELEV is over valued or under valued. Whether Elevation Oncology, Inc. is cheap or expensive depends on the assumptions which impact Elevation Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELEV.